Cell and Animal Models for SARS-CoV-2 Research

During the last two years following the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, development of potent antiviral drugs and vaccines has been a global health priority. In this context, the understanding of virus pathophysiology, the identification of associated therapeutic targets, and the screening of potential effective compounds have been indispensable advancements. It was therefore of primary importance to develop experimental models that recapitulate the aspects of the human disease in the best way possible. This article reviews the information concerning available SARS-CoV-2 preclinical models during that time, including cell-based approaches and animal models. We discuss their evolution, their advantages, and drawbacks, as well as their relevance to drug effectiveness evaluation.

[1]  K. To,et al.  A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge , 2022, Nature Communications.

[2]  T. Pandita,et al.  Breakthroughs and Applications of Organ-on-a-Chip Technology , 2022, Cells.

[3]  H. S. Rho,et al.  A guide to the organ-on-a-chip , 2022, Nature Reviews Methods Primers.

[4]  E. Dora,et al.  Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model , 2022, Science Translational Medicine.

[5]  J. Chan,et al.  Animal models in SARS-CoV-2 research , 2022, Nature Methods.

[6]  R. Plemper,et al.  SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19 , 2022, bioRxiv.

[7]  A. García-Sastre,et al.  Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs , 2021, mBio.

[8]  K. To,et al.  Low dose inocula of SARS-CoV-2 Alpha variant transmits more efficiently than earlier variants in hamsters , 2021, Communications Biology.

[9]  A. Lorusso,et al.  Long‐term persistence of neutralizing SARS‐CoV‐2 antibodies in pets , 2021, Transboundary and emerging diseases.

[10]  Robert J. Fischer,et al.  SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters , 2021, Nature Communications.

[11]  A. García-Sastre,et al.  Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer , 2021, bioRxiv.

[12]  N. Hulo,et al.  Estimating clinical SARS-CoV-2 infectiousness in Vero E6 and primary airway epithelial cells , 2021, The Lancet Microbe.

[13]  Y. Bi,et al.  A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection , 2021, Nature Communications.

[14]  Su-Jin Park,et al.  Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets , 2021, Nature Communications.

[15]  Jordan J. Clark,et al.  A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 , 2021, Nature Communications.

[16]  M. Drebot,et al.  SARS-CoV-2 infection and transmission in the North American deer mouse , 2021, Nature Communications.

[17]  M. Zimic,et al.  Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima – Peru , 2021, bioRxiv.

[18]  W. de Lau,et al.  A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses , 2021, Nature Communications.

[19]  D. Altmann,et al.  Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 , 2021, npj Vaccines.

[20]  D. Altmann,et al.  Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 , 2021, npj Vaccines.

[21]  Rani K. Powers,et al.  A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics , 2021, Nature Biomedical Engineering.

[22]  Huanchun Chen,et al.  Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice , 2021, EBioMedicine.

[23]  G. Ebel,et al.  SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for spillback to New World rodents , 2021, PLoS pathogens.

[24]  L. Szekely,et al.  Cell-type-resolved quantitative proteomics map of interferon response against SARS-CoV-2 , 2021, iScience.

[25]  K. Jarnagin,et al.  Animal models for SARS-Cov2/Covid19 research-A commentary , 2021, Biochemical Pharmacology.

[26]  A. Costa,et al.  ACE2 OVEREXPRESSION CHANGES THE SARS-COV-2 INFECTION PROFILE IN BEAS-2B CELLS , 2021, Cytotherapy.

[27]  F. Grieder,et al.  Nonhuman primate models for SARS-CoV-2 research: Consider alternatives to macaques , 2021, Lab Animal.

[28]  Brian T. Emmer,et al.  ACE2 protein expression within isogenic cell lines is heterogeneous and associated with distinct transcriptomes , 2021, bioRxiv.

[29]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[30]  Jin Yu Organoids: A New Model for SARS-CoV-2 Translational Research , 2021, International journal of stem cells.

[31]  A. Nicholson,et al.  Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19 , 2021, Nature Communications.

[32]  J. Miyan,et al.  Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. , 2021, Annual review of pharmacology and toxicology.

[33]  H. Jäck,et al.  SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization , 2021, bioRxiv.

[34]  T. Rana,et al.  Revealing Tissue-Specific SARS-CoV-2 Infection and Host Responses using Human Stem Cell-Derived Lung and Cerebral Organoids , 2021, Stem Cell Reports.

[35]  Henrique S. Fernandes,et al.  In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion , 2021, bioRxiv.

[36]  A. Gupta,et al.  A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. , 2021, Journal of the American Society of Nephrology : JASN.

[37]  Charles Y. Tan,et al.  BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.

[38]  S. Einav,et al.  Retracted papers on SARS-CoV-2 and COVID-19 , 2021, British Journal of Anaesthesia.

[39]  M. Palmer,et al.  Susceptibility of White-Tailed Deer (Odocoileus virginianus) to SARS-CoV-2 , 2021, Journal of Virology.

[40]  Qiang Zhou,et al.  AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells , 2021, Cell Research.

[41]  C. Turner,et al.  Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity , 2021, Nature Communications.

[42]  Xiaozhong Peng,et al.  A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome , 2021, Signal Transduction and Targeted Therapy.

[43]  P. McPherson,et al.  SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis , 2021, Journal of Biological Chemistry.

[44]  C. Hallam,et al.  Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets , 2020, Nature microbiology.

[45]  Mauro J. Muraro,et al.  An organoid‐derived bronchioalveolar model for SARS‐CoV‐2 infection of human alveolar type II‐like cells , 2020, The EMBO journal.

[46]  T. Song,et al.  SARS-CoV-2 induced intestinal responses with a biomimetic human gut-on-chip , 2020, Science Bulletin.

[47]  M. Hoque,et al.  Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes , 2020, Cancers.

[48]  Grace X. Y. Zheng,et al.  Progenitor identification and SARS-CoV-2 infection in human distal lung organoids , 2020, Nature.

[49]  R. Plemper,et al.  Therapeutically Administered Ribonucleoside Analogue MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets , 2020, Nature microbiology.

[50]  T. Geisbert,et al.  Establishment of an African green monkey model for COVID-19 and protection against reinfection , 2020, Nature immunology.

[51]  A. Eid,et al.  Hydroxychloroquine in COVID-19 Patients: Pros and Cons , 2020, Frontiers in Pharmacology.

[52]  A. Gruber,et al.  The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection , 2020, Cell Reports.

[53]  P. Maes,et al.  STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters , 2020, Nature Communications.

[54]  M. Koopmans,et al.  Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans , 2020, Science.

[55]  T. Beccari,et al.  Pilot study for the evaluation of safety profile of a potential inhibitor of SARS-CoV-2 endocytosis , 2020, Acta bio-medica : Atenei Parmensis.

[56]  J. Qiu,et al.  Long-Term Modeling of SARS-CoV-2 Infection of In Vitro Cultured Polarized Human Airway Epithelium , 2020, mBio.

[57]  Yuanlin Song,et al.  COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms , 2020, Signal Transduction and Targeted Therapy.

[58]  D. O’Connor,et al.  Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models , 2020, Nature Reviews Immunology.

[59]  M. Mohan,et al.  Animal Models for SARS-CoV-2 research: A Comprehensive Literature Review. , 2020, Transboundary and emerging diseases.

[60]  Jared L. Johnson,et al.  Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids , 2020, Nature.

[61]  Channabasavaiah B. Gurumurthy,et al.  Genetically modified mouse models to help fight COVID-19 , 2020, Nature Protocols.

[62]  J. Qin,et al.  Biomimetic Human Disease Model of SARS‐CoV‐2‐Induced Lung Injury and Immune Responses on Organ Chip System , 2020, Advanced science.

[63]  L. Steinmetz,et al.  Single‐cell analyses reveal SARS‐CoV‐2 interference with intrinsic immune response in the human gut , 2020, bioRxiv.

[64]  T. Bestebroer,et al.  SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance , 2020, Nature Communications.

[65]  A. Thitithanyanont,et al.  Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana , 2020, Scientific Reports.

[66]  Madeline A. Lancaster,et al.  SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids , 2020, Cell Stem Cell.

[67]  M. Deininger,et al.  Imatinib is not a potent anti-SARS-CoV-2 drug , 2020, Leukemia.

[68]  S. Vandewoude,et al.  Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats , 2020, Proceedings of the National Academy of Sciences.

[69]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[70]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[71]  Lisa E. Gralinski,et al.  A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice , 2020, Cell.

[72]  Lisa E. Gralinski,et al.  Animal models for COVID-19 , 2020, Nature.

[73]  Catherine Z. Chen,et al.  Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium , 2020, Cell Stem Cell.

[74]  A. Gruber,et al.  SARS‐CoV‐2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID‐19 pneumonia in a well‐established small animal model , 2020, Transboundary and emerging diseases.

[75]  H. Clevers,et al.  Establishment of patient-derived cancer organoids for drug-screening applications , 2020, Nature Protocols.

[76]  Jay Gopalakrishnan,et al.  SARS‐CoV‐2 targets neurons of 3D human brain organoids , 2020, The EMBO journal.

[77]  M. Marshall The lasting misery of coronavirus long-haulers , 2020, Nature.

[78]  Rajarshi Pal,et al.  Human induced pluripotent stem cell-derived lung epithelial system for SARS-CoV-2 infection modeling and its potential in drug repurposing. , 2020, Stem cells and development.

[79]  Lisa E. Gralinski,et al.  A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.

[80]  W. Dowling,et al.  Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients , 2020, Nature Communications.

[81]  D. Ho,et al.  Modeling COVID-19 with Human Pluripotent Stem Cell-Derived Cells Reveals Synergistic Effects of Anti-inflammatory Macrophages with ACE2 Inhibition Against SARS-CoV-2 , 2020, Research square.

[82]  Y. Itoh,et al.  Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques , 2020, bioRxiv.

[83]  N. Patel,et al.  NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, bioRxiv.

[84]  G. Yuan,et al.  Identification of potential key genes for SARS-CoV-2 infected human bronchial organoids based on bioinformatics analysis , 2020, bioRxiv.

[85]  Xiaozhong Peng,et al.  Comparison of nonhuman primates identified the suitable model for COVID-19 , 2020, Signal Transduction and Targeted Therapy.

[86]  D. Diel,et al.  SARS-COV-2 INFECTION AND LONGITUDINAL FECAL SCREENING IN MALAYAN TIGERS (PANTHERA TIGRIS JACKSONI), AMUR TIGERS (PANTHERA TIGRIS ALTAICA ), AND AFRICAN LIONS (PANTHERA LEO KRUGERI) AT THE BRONX ZOO, NEW YORK, USA , 2020, Journal of Zoo and Wildlife Medicine.

[87]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[88]  Yong-tang Zheng,et al.  Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques , 2020, Zoological research.

[89]  Wenling Wang,et al.  Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells , 2020, Nature Communications.

[90]  T. Geisbert,et al.  Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase , 2020, Virology Journal.

[91]  Yan Li,et al.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.

[92]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[93]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[94]  Rebecca J. Loomis,et al.  Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.

[95]  D. Lauffenburger,et al.  Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[96]  S. Chanda,et al.  Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing , 2020, Nature.

[97]  S. Tong,et al.  From People to Panthera: Natural SARS-CoV-2 Infection in Tigers and Lions at the Bronx Zoo , 2020, mBio.

[98]  Yong-tang Zheng,et al.  COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2 , 2020, Zoological research.

[99]  X. de Lamballerie,et al.  Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates , 2020, Nature.

[100]  M. Müller,et al.  Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 , 2020, Nature.

[101]  C. Hallam,et al.  Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice , 2020, Nature Communications.

[102]  B. Clotet,et al.  Pigs are not susceptible to SARS‐CoV‐2 infection but are a model for viral immunogenicity studies , 2020, Transboundary and Emerging Diseases.

[103]  Timothy A. Blenkinsop,et al.  SARS-CoV-2 Infection of Ocular Cells from Human Adult Donor Eyes and hESC-Derived Eye Organoids. , 2020, SSRN.

[104]  H. Mouquet,et al.  Syncytia formation by SARS‐CoV‐2‐infected cells , 2020, bioRxiv.

[105]  M. Koopmans,et al.  Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison) , 2020, Veterinary pathology.

[106]  X. de Lamballerie,et al.  Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model , 2020, Nature Communications.

[107]  M. Beer,et al.  SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study , 2020, The Lancet Microbe.

[108]  J. Knoblich,et al.  Human organoids: model systems for human biology and medicine , 2020, Nature Reviews Molecular Cell Biology.

[109]  A. García-Sastre,et al.  Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection , 2020, bioRxiv.

[110]  Chuan Qin,et al.  Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques , 2020, Science.

[111]  R. Baric,et al.  Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.

[112]  Jessie Huang,et al.  SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response , 2020, bioRxiv.

[113]  C. Yao,et al.  SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery , 2020, bioRxiv.

[114]  W. Petri,et al.  Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection , 2020, bioRxiv.

[115]  P. Brun,et al.  Ocular Surface Expression of SARS-CoV-2 Receptors , 2020, Ocular immunology and inflammation.

[116]  Joshua L. Moore,et al.  Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure , 2020, bioRxiv.

[117]  Tokiko Watanabe,et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[118]  J. Flynn,et al.  SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts , 2020, bioRxiv.

[119]  S. Weaver,et al.  “Acute Respiratory Distress and Cytokine Storm in Aged, SARS-CoV-2 Infected African Green Monkeys, but not in Rhesus Macaques” , 2020, bioRxiv.

[120]  Amogelang R. Raphenya,et al.  Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.

[121]  R. Field,et al.  The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device , 2020, ACS central science.

[122]  Larissa B. Thackray,et al.  A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies , 2020, Cell.

[123]  Rongchang Chen,et al.  Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment , 2020, Cell.

[124]  A. Gruber,et al.  Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters , 2020, bioRxiv.

[125]  C. Hallam,et al.  SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species , 2020, bioRxiv.

[126]  M. Koopmans,et al.  SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[127]  F. Yu,et al.  SARS-CoV-2 infection and stem cells: Interaction and intervention , 2020, Stem Cell Research.

[128]  Kwok-Hung Chan,et al.  Long SARS-CoV-2 nucleocapsid sequences in blood monocytes collected soon after hospital admission , 2020, bioRxiv.

[129]  Kazuo Takayama In Vitro and Animal Models for SARS-CoV-2 research , 2020, Trends in Pharmacological Sciences.

[130]  Matthew J. O’Meara,et al.  Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 , 2020, bioRxiv.

[131]  Lisa E. Gralinski,et al.  SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , 2020, Cell.

[132]  T. Zhao,et al.  A Mouse Model of SARS-CoV-2 Infection and Pathogenesis , 2020, Cell Host & Microbe.

[133]  Eun Ji Kim,et al.  Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets , 2020, mBio.

[134]  P. Zhou,et al.  Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2 , 2020, Cell.

[135]  P. Sorger,et al.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.

[136]  S. Ciesek,et al.  Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.

[137]  D. Chu,et al.  Infection of dogs with SARS-CoV-2 , 2020, Nature.

[138]  H. Yen,et al.  Pathogenesis and transmission of SARS-CoV-2 in golden hamsters , 2020, Nature.

[139]  M. Veit,et al.  Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts , 2020, Journal of Virology.

[140]  Y. Kawaoka,et al.  Transmission of SARS-CoV-2 in Domestic Cats. , 2020, The New England journal of medicine.

[141]  O. Tsang,et al.  Infection of bat and human intestinal organoids by SARS-CoV-2 , 2020, Nature Medicine.

[142]  H. Chen,et al.  SARS-CoV-2 activates lung epithelia cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients by single-cell sequencing , 2020, medRxiv.

[143]  E. Fischer,et al.  Respiratory disease in rhesus macaques inoculated with SARS-CoV-2 , 2020, Nature.

[144]  Malik Peiris,et al.  Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures , 2020, The Lancet Respiratory Medicine.

[145]  V. Jhanji,et al.  Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea , 2020, Eye.

[146]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[147]  Fang Li,et al.  Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[148]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[149]  Jared L. Johnson,et al.  Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids , 2020, bioRxiv.

[150]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[151]  Xiaozhong Peng,et al.  Susceptibility of tree shrew to SARS-CoV-2 infection , 2020, Scientific Reports.

[152]  Juan F Burgueño,et al.  Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD , 2020, Inflammatory bowel diseases.

[153]  Hans Clevers,et al.  SARS-CoV-2 productively infects human gut enterocytes , 2020, Science.

[154]  S. Allison SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 , 2020, Nature Reviews Nephrology.

[155]  André Machado Siqueira,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[156]  O. Tsang,et al.  Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.

[157]  V. Cagno,et al.  SARS-CoV-2 cellular tropism , 2020, The Lancet Microbe.

[158]  Koichi Yuki,et al.  COVID-19 pathophysiology: A review , 2020, Clinical Immunology.

[159]  Natacha S. Ogando,et al.  SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology , 2020, bioRxiv.

[160]  S. Ciesek,et al.  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection , 2020 .

[161]  T. Kuiken,et al.  Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model , 2020, Science.

[162]  Martin Stahl,et al.  Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 , 2020, Cell.

[163]  M. Koopmans,et al.  SARS-CoV-2 is transmitted via contact and via the air between ferrets , 2020, bioRxiv.

[164]  Li Yang,et al.  Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids , 2020, Protein & Cell.

[165]  S. Anzick,et al.  Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.

[166]  Donald E. Ingber,et al.  Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics , 2020 .

[167]  Kohei Oishi,et al.  Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics , 2020, bioRxiv.

[168]  Zhanju Liu,et al.  Clinical Features of COVID-19-Related Liver Functional Abnormality , 2020, Clinical Gastroenterology and Hepatology.

[169]  Baoying Huang,et al.  Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 , 2020, Science.

[170]  J. Aronson,et al.  Chloroquine and hydroxychloroquine in covid-19 , 2020, BMJ.

[171]  Xiaotao Lu,et al.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice , 2020, Science Translational Medicine.

[172]  Eun-Ha Kim,et al.  Infection and Rapid Transmission of SARS-CoV-2 in Ferrets , 2020, Cell Host & Microbe.

[173]  V. Soldatov,et al.  On the way from SARS-CoV-sensitive mice to murine COVID-19 model , 2020 .

[174]  Roland Eils,et al.  SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells , 2020, The EMBO journal.

[175]  E. Chorin,et al.  The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin , 2020, medRxiv.

[176]  Y. Yazdanpanah,et al.  Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia , 2020, bioRxiv.

[177]  Kaili Wu,et al.  Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China , 2020, JAMA ophthalmology.

[178]  Lu Lu,et al.  Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.

[179]  K. Hashimoto,et al.  Nervous system involvement after infection with COVID-19 and other coronaviruses , 2020, Brain, Behavior, and Immunity.

[180]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[181]  K. To,et al.  Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[182]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[183]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[184]  Jun Zheng SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat , 2020, International journal of biological sciences.

[185]  H. Gao,et al.  Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques , 2020, Nature Communications.

[186]  H. Gao,et al.  Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2 , 2020, bioRxiv.

[187]  Fumihiro Kato,et al.  Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.

[188]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[189]  Vineet D. Menachery,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States , 2020, Emerging infectious diseases.

[190]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[191]  X. de Lamballerie,et al.  Of chloroquine and COVID-19 , 2020, Antiviral Research.

[192]  Xiang Xie,et al.  COVID-19 and the cardiovascular system , 2020, Nature Reviews Cardiology.

[193]  Philippe Brouqui,et al.  Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 , 2020, International Journal of Antimicrobial Agents.

[194]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[195]  Shinji Makino,et al.  Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient , 2020, bioRxiv.

[196]  Daniel Bell SARS-CoV , 2020, Radiopaedia.org.

[197]  P. Zhou,et al.  Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques , 2020, Cell Research.

[198]  Taojiao Wang,et al.  Caution on Kidney Dysfunctions of COVID-19 Patients , 2020, medRxiv.

[199]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[200]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[201]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[202]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[203]  Jian-Piao Cai,et al.  Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target , 2020, Emerging microbes & infections.

[204]  J. Penninger,et al.  Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells , 2020, Emerging microbes & infections.

[205]  N. Yaegashi,et al.  Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals , 2020, The veterinary quarterly.

[206]  A. García-Sastre,et al.  Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection , 2020, Emerging microbes & infections.

[207]  H. Clevers,et al.  Organoids in immunological research , 2019, Nature Reviews Immunology.

[208]  A. Walls,et al.  Structural basis for human coronavirus attachment to sialic acid receptors , 2019, Nature Structural & Molecular Biology.

[209]  Jamie Munro,et al.  Trends in clinical success rates and therapeutic focus , 2019, Nature Reviews Drug Discovery.

[210]  C. Wang,et al.  Phenotypic characterization of a novel type 2 diabetes animal model in a SHANXI MU colony of Chinese hamsters , 2019, Endocrine.

[211]  Yuanyuan Han,et al.  Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo , 2017, The Journal of general virology.

[212]  T. Tumpey,et al.  Complexities in Ferret Influenza Virus Pathogenesis and Transmission Models , 2016, Microbiology and Molecular Reviews.

[213]  Lisa E. Gralinski,et al.  SARS-like WIV1-CoV poised for human emergence , 2016, Proceedings of the National Academy of Sciences.

[214]  R. Dijkman,et al.  Coronaviruses and the human airway: a universal system for virus-host interaction studies , 2016, Virology Journal.

[215]  N. Sardesai,et al.  A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates , 2015, Science Translational Medicine.

[216]  Ulas Bagci,et al.  Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.

[217]  R. A. Karssemeijer,et al.  A 3-D enteroid-based model to study T-cell and epithelial cell interaction. , 2015, Journal of immunological methods.

[218]  H. Goossens,et al.  Culturing of respiratory viruses in well-differentiated pseudostratified human airway epithelium as a tool to detect unknown viruses , 2014, Influenza and other respiratory viruses.

[219]  Krystal L. Matthews,et al.  Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. , 2014, The Journal of general virology.

[220]  L. Poon,et al.  Entry of Influenza A Virus with a α2,6-Linked Sialic Acid Binding Preference Requires Host Fibronectin , 2012, Journal of Virology.

[221]  R. Baric,et al.  Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease , 2011, Journal of Virology.

[222]  K. Schughart,et al.  TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells , 2010, Journal of Virology.

[223]  J. Orenstein,et al.  Human airway epithelial cell culture to identify new respiratory viruses: Coronavirus NL63 as a model , 2008, Journal of Virological Methods.

[224]  Andrew Pekosz,et al.  An immunosuppressed Syrian golden hamster model for SARS-CoV infection , 2008, Virology.

[225]  Kate E. Jones,et al.  Global trends in emerging infectious diseases , 2008, Nature.

[226]  Qianjun Li,et al.  The SARS-CoV ferret model in an infection–challenge study , 2008, Virology.

[227]  Ron A M Fouchier,et al.  Immunopathology and Infectious Disease Human and Avian Influenza Viruses Target Different Cells in the Lower Respiratory Tract of Humans and Other Mammals , 2010 .

[228]  Amy C. Sims,et al.  SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium , 2007, Virus Research.

[229]  Jiang Gu,et al.  Pathology and Pathogenesis of Severe Acute Respiratory Syndrome , 2007, The American Journal of Pathology.

[230]  David K. Meyerholz,et al.  Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.

[231]  C. Schwegmann-Wessels,et al.  Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. , 2006, The Journal of general virology.

[232]  T. Greenough,et al.  Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters , 2006, The Journal of infectious diseases.

[233]  Lucy A. Perrone,et al.  Apical Entry and Release of Severe Acute Respiratory Syndrome-Associated Coronavirus in Polarized Calu-3 Lung Epithelial Cells , 2005, Journal of Virology.

[234]  T. Greenough,et al.  Pneumonitis and Multi-Organ System Disease in Common Marmosets (Callithrix jacchus) Infected with the Severe Acute Respiratory Syndrome-Associated Coronavirus , 2005, The American Journal of Pathology.

[235]  Krishna Shankara Narayanan,et al.  Exogenous ACE2 Expression Allows Refractory Cell Lines To Support Severe Acute Respiratory Syndrome Coronavirus Replication , 2005, Journal of Virology.

[236]  B. Murphy,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters , 2005, Journal of Virology.

[237]  John A. Maher,et al.  The Ferret: An Animal Model to Study Influenza Virus , 2004, Lab Animal.

[238]  R. Sanchez,et al.  The current and future organisational structure of the OIE (World Organisation for Animal Health) , 2003 .

[239]  Albert D. M. E. Osterhaus,et al.  SARS virus infection of cats and ferrets , 2003, Nature.

[240]  Wilson Smith,et al.  A Virus obtained from influenza patients , 1933 .

[241]  World Health Organization,et al.  Transmission of SARS-CoV-2: implications for infection prevention precautions , 2020 .

[242]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[243]  K. B. Renegar Influenza virus infections and immunity: a review of human and animal models. , 1992, Laboratory animal science.

[244]  P. Demoly,et al.  [Transgenic mice]. , 1992, Annales de dermatologie et de venereologie.